Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
CONCLUSION: NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.PMID:38657187 | DOI:10.1200/JCO.23.01983 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Niklas Kl ümper Ngoc Khanh Tran Stefanie Zsch äbitz Oliver Hahn Thomas B üttner Florian Roghmann Christian Bolenz Friedemann Zengerling Constantin Schwab Dora Nagy Marieta Toma Glen Kristiansen Hendrik Heers Philipp Ivanyi G ünter Niegisch Camilla Mar Source Type: research
The use of complementary and alternative medicine and approaches to coping with stress in women with breast cancer: a cross-sectional study
CONCLUSIONS: One-third of women were using CAM and had a good level of approaches to coping with stress. Healthcare providers, especially gynecology-oncology nurses, should provide counseling on CAMs and develop strategies for coping with stress for women with breast cancer.PMID:38657706 | DOI:10.1016/j.enfcle.2024.04.007 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Ekin Dila Topalo ğlu Ören Seda Doruko ğlu G ül Ertem Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib
Clin Transl Med. 2024 Apr;14(4):e1662. doi: 10.1002/ctm2.1662.NO ABSTRACTPMID:38658768 | DOI:10.1002/ctm2.1662 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Steffan T Nawrocki Claudia M Espitia Maria Janina Carrera Espinoza Trace M Jones Madison E Gamble Sruthi Sureshkumar Mengyang Chang Wei Wang Jennifer S Carew Source Type: research
CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1
CONCLUSION: The novel protein PDE5A-500aa encoded by circPDE5A can act as an inhibitor of the PI3K/AKT signaling pathway to inhibit the progression of ESCC by promoting USP14-mediated de-ubiquitination of PIK3IP1 and may serve as a potential target for the development of therapeutic agents.PMID:38658954 | DOI:10.1186/s13046-024-03054-3 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Kai Lei Ruihao Liang Jialu Liang Nan Lu Jing Huang Ke Xu Binghua Tan Kexi Wang Yicheng Liang Wenjian Wang Huayue Lin Minghui Wang Source Type: research
Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer
CONCLUSIONS: Pretreatment microRNA profiles could be used to select subgroups of patients who benefited more from primary debulking surgery or neoadjuvant chemotherapy and might contribute to selecting the optimal primary treatment modality in advanced high-grade serous ovarian cancer patients.PMID:38651188 | DOI:10.1093/jjco/hyae051 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Takashi Uehara Juntaro Matsuzaki Hiroshi Yoshida Yuto Ogawa Junichiro Miura Hitoshi Fujimiya Yusuke Yamamoto Junpei Kawauchi Satoko Takizawa Kan Yonemori Hiromi Sakamoto Ken Kato Mitsuya Ishikawa Takahiro Ochiya Source Type: research
Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas
CONCLUSIONS: This is the first study to suggest a role for the breast cancer predisposition gene, CHEK2, in pituitary tumorigenesis, with pathogenic/likely pathogenic variants found in 3% of patients with pituitary adenomas. As pituitary adenomas are relatively common and typically lack classical autosomal dominant family histories, risk alleles - such as these variants found in CHEK2 - might be a significant contributor to pituitary adenoma risk in the general population.PMID:38651569 | DOI:10.1210/clinem/dgae268 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Sunita M C De Sousa Ann McCormack Andreas Orsmond Angeline Shen Christopher J Yates Roderick Clifton-Bligh Stephen Santoreneos James King Jinghua Feng John Toubia David J Torpy Hamish S Scott Source Type: research
Fulfilling the Role of a Parent While Undergoing Treatment for Cancer: A Review of the Literature and the Potential Impact of Childcare Support on Cancer Outcomes
Am J Clin Oncol. 2024 Apr 23. doi: 10.1097/COC.0000000000001102. Online ahead of print.ABSTRACTBreast cancer is the most prevalent malignancy among adolescents and young adults (AYAs). Despite the efficacy of chemotherapy, AYA patients contend with psychosocial challenges, including psychological distress and financial toxicity, exacerbated further by those with dependent children. Parenting responsibilities intersect with cancer care, impacting both family dynamics and treatment adherence. Despite recognized needs, however, the impact of parenting concerns or even parenting status and the presence of dependents has not be...
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Kang Woo Kim Mary Lopresti Stephanie L Graff Sabrina Witherby Don S Dizon Mary Anne Fenton Source Type: research
DNA damage, obesity and obesity-related health complications: what are new data telling us?
This article surveys new data that support these contentions.RECENT FINDINGS: Whole exome sequencing analyses have identified rare variants linked to high BMI and adiposity. Two of the identified genes are linked to DNA damage and DNA repair, suggesting that DNA damage itself may play a role in the cause of obesity. It has also been recognized that obesity increases DNA damage in breast tissue of carriers of BRCA mutations and rates of tumour formation in BRCA1+ mice, indicating effect of obesity on cancer development in high-risk populations. In addition, obesity promotes cancer cell chemoresistance by decreasing fatty ac...
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Marta W łodarczyk Gra żyna Nowicka Source Type: research
Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016
CONCLUSION: Acromegaly is associated with increased incidence of all cancers but not thyroid or colon cancer and no increase in cancer mortality. Excess mortality is due to vascular and respiratory disease. The risk is highest in the first 5 years following diagnosis and is mitigated by normalising GH levels.PMID:38652736 | DOI:10.1111/cen.15060 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Steve Orme Richard McNally Peter W James Jessica Davis John Ayuk Claire Higham John Wass UK Acromegaly Register Study Group Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
The Introduction of Magtrace Lymphatic Tracer for Axillary Sentinel Node Biopsy for Breast Cancer in a Rural Scottish District General Hospital: Initial Experience, Perspectives, Outcomes and Learning Curves
CONCLUSION: This study suggests that introducing Magtrace was feasible and safe in the context of a rural breast cancer service. A possible strategy to ameliorate the learning curve associated with these procedures is the routine dual localisation in the initial phases of performing Magtrace localisation.PMID:38653647 | DOI:10.1016/j.clbc.2024.03.013 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Chia Yew Kong Jacob Williams Niroshini Hemadasa Dermot Murphy Maria Bews-Hair Source Type: research
Improving quality of life after breast cancer: a comparison of two microsurgical treatment options for breast cancer-related lymphedema (BCRL)
CONCLUSIONS: Both VLNT and LVA offer significant improvement for patients suffering from chronic BCRL. VLNT shows an even greater potential for improvement in more severe cases of BCRL, but involves a higher risk for (mostly minor) complications.PMID:38653874 | PMC:PMC11039536 | DOI:10.1007/s10238-024-01344-w (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Katrin Seidenstuecker Sonia Fertsch Alina A Ghazaleh Adriano Fabi Julia Stoffel Julia Bukowiecki Andreas Wolter Soheila Aghlmandi Anshoo Nadella Florian S Halbeisen Christoph Andree Martin D Haug Dirk J Schaefer Tristan M Handschin Elisabeth A Kappos Source Type: research
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
CONCLUSION: In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.PMID:38653928 | DOI:10.1007/s12094-024-03409-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Olga Mart ínez-Sáez Javier Cort és Eva Ciruelos Mercedes Mar ín-Aguilera Gloria Gonz ález Laia Par é Adriana Herrera Patricia Villagrasa-Gonz ález Aleix Prat Miguel Mart ín Source Type: research
